drugset / Trial / NCT01178658
Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma
Phase 2
Unknown
42 enrolled
Seoul National University Hospital
Asan Medical Center · collabInje University · collabSeverance Hospital · collabUlsan University Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and toxicity of busulfan, etoposide, cytarabine and melphalan (BuEAM) as a conditioning for autologous stem cell transplantation in patients with non-Hodgkin lymphoma.
Timeline
- Start
- 2010-07
- Primary completion
- 2014-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | 3.2 mg/kg | Intravenous |
| Subject | Cytarabine | Small molecule | 1 g | — |
| Subject | Etoposide | Small molecule | 400 mg/m2 | — |
| Subject | Melphalan | Small molecule | 140 mg/m2 | — |